system
inflamm
may
reflect
infect
appropri
therapi
includ
support
care
use
antimicrobi
agent
inde
earli
initi
antibiot
key
import
manag
sepsi
howev
inflamm
may
also
aris
noninfecti
caus
includ
pancreat
cardiac
ischemia
bowel
perfor
vascul
pulmonari
embol
current
clinic
practic
initi
empir
antibiot
therapi
prior
identif
infecti
agent
base
treatment
guidelin
knowledg
local
microbiom
unfortun
confirm
infect
may
take
sever
day
error
antibiot
choic
lead
signific
increas
mortal
wherea
overus
antibiot
foster
bacteri
resist
therefor
method
differenti
inflamm
due
infect
inflamm
due
caus
particularli
valuabl
two
biomark
wide
studi
diagnosi
infecti
inflammationcreact
protein
crp
procalcitonin
pct
found
vari
success
clinic
context
center
reli
heavili
marker
other
eschew
use
almost
entir
chapter
present
evid
use
diagnosi
infect
manag
antibiot
therapi
intens
care
unit
icu
context
name
abil
precipit
cpolysaccharid
streptococcu
pneumonia
crp
first
acutephas
protein
describ
subsequ
identifi
serum
patient
wide
varieti
infecti
diseas
crp
exquisit
sensit
marker
system
inflamm
infect
tissu
damag
central
compon
nonspecif
acutephas
respons
crp
bind
phosphocholin
constitu
bacteri
fungal
polysaccharid
well
compon
damag
cell
membran
calciumdepend
manner
princip
produc
hepatocyt
express
strongli
stimul
interleukin
il
proinflammatori
cytokin
bound
phosphocholin
crp
recogn
therebi
activ
classic
complement
pathway
crp
multitud
downstream
effect
proinflammatori
antiinflammatori
stimul
phagocytosi
bind
immunoglobulin
fcg
receptor
well
increas
releas
antiinflammatori
cytokin
convers
downregul
proinflammatori
cytokin
interferong
crp
play
activ
role
immun
respons
infect
polymorph
shown
increas
suscept
mortal
invas
pneumococc
diseas
crp
nonspecif
marker
inflamm
respons
acutephas
stimulu
serum
crp
concentr
rise
quickli
doubl
everi
hour
plasma
halflif
crp
around
hour
peak
level
detect
approxim
hour
singl
stimulu
healthi
adult
median
concentr
crp
mgl
may
increas
mgl
context
inflamm
acutephas
stimulu
past
crp
level
return
normal
within
day
howev
patient
sepsi
show
persist
high
crp
level
least
day
like
longer
addit
infect
caus
crp
elev
includ
pancreat
trauma
burn
rheumatolog
diseas
pericard
inflammatori
bowel
diseas
solid
tumor
hematolog
malign
howev
extrem
elev
crp
level
mgl
associ
infect
patient
crp
wide
studi
marker
bacteri
infect
icu
patient
popul
elev
patient
infect
rel
noninfecti
system
inflamm
even
adjust
sever
ill
ideal
cutoff
diagnosi
infect
rang
mgl
sensit
specif
estim
vari
metaanalysi
provid
pool
sensit
specif
diagnosi
bacteri
infect
rel
noninfecti
inflamm
pediatr
popul
ideal
cutoff
typic
lower
mgl
crp
level
tend
lower
system
viral
fungal
infect
system
bacteri
infect
context
viral
infect
interferona
may
inhibit
crp
product
hepatocyt
howev
often
overlap
crp
level
patient
bacteri
nonbacteri
infect
make
difficult
distinguish
metaanalysi
crp
communityacquir
pneumonia
show
wide
vari
sensit
specif
estim
biomark
use
differenti
infect
noninfecti
caus
inflamm
alexandra
binni
joel
lage
claudia
c
do
santo
signific
heterogen
similarli
metaanalysi
patient
fever
unknown
origin
fail
show
util
crp
identifi
patient
bacteri
vs
nonbacteri
infect
howev
crp
may
greater
util
distinguish
bacteri
nonbacteri
ill
critic
ill
popul
gener
hospit
popul
studi
icu
patient
influenza
icu
patient
bacteri
pneumonia
crp
level
much
lower
popul
mean
mgl
vs
mgl
studi
crp
cutoff
mgl
identifi
patient
bacteri
pneumonia
sensit
specif
similarli
cohort
studi
patient
presum
sever
acut
respiratori
syndrom
sar
reveal
averag
crp
level
mgl
popul
limit
data
avail
crp
context
fungal
infect
singlecent
studi
immunocompromis
patient
show
crp
level
elev
context
invas
fungal
infect
rang
mgl
albeit
lesser
degre
patient
bacteremia
rang
mgl
anoth
studi
postsurg
patient
high
risk
fungal
infect
show
crp
cutoff
mgl
help
distinguish
bacteri
fungal
infect
sensit
specif
thu
high
crp
level
favor
bacteri
fungal
caus
infect
work
requir
clarifi
appropri
cutoff
well
determin
sensit
specif
util
crp
infect
marker
increas
combin
marker
et
al
report
prospect
observ
studi
icu
patient
crp
mgl
temperatur
specif
sensit
infecti
caus
inflamm
separ
studi
infect
probabl
score
incorpor
crp
mgl
along
fever
tachycardia
elev
white
blood
cell
count
tachypnea
elev
sequenti
organ
failur
assess
sofa
score
show
nearli
sensit
specif
diagnos
infect
icu
patient
crp
also
shown
util
diagnosi
postop
infect
particularli
patient
undergo
major
abdomin
surgeri
crp
level
alway
rise
postop
peak
around
postop
day
howev
persist
high
crp
level
suggest
infect
retrospect
studi
shown
elev
postop
crp
level
mgl
mgl
sensit
specif
infect
prospect
studi
gener
confirm
result
prospect
studi
mix
surgic
patient
show
crp
mgl
sensit
specif
infect
separ
studi
patient
show
crp
mgl
sensit
specif
anastomot
leak
larg
prospect
studi
current
underway
patient
provid
clariti
issu
daili
crp
measur
studi
strategi
earli
detect
nosocomi
infect
icu
prospect
observ
studi
et
al
evalu
daili
crp
measur
icu
patient
document
icuacquir
infect
n
vs
success
icu
discharg
without
infect
n
patient
icuacquir
infect
temperatur
crp
level
increas
significantli
day
lead
diagnosi
p
absolut
crp
mgl
daili
crp
variat
mgl
characterist
infect
combin
show
sensit
specif
icuacquir
infect
crp
also
use
monitor
antibiot
therapi
critic
ill
popul
schmit
vincent
conduct
prospect
observ
studi
icu
patient
communityacquir
nosocomi
infect
favor
respons
antibiot
requir
chang
antibiot
determin
treat
physician
requir
procedur
control
infect
mean
crp
level
rose
day
initi
antibiot
day
group
howev
patient
favor
respons
antibiot
show
rapid
decreas
day
compar
patient
requir
chang
antibiot
increas
crp
mgl
first
hour
therapi
associ
ineffect
antibiot
therapi
sensit
specif
treat
physician
blind
crp
level
rise
crp
may
contribut
decis
chang
antibiot
patient
separ
cohort
studi
patient
ventilatorassoci
pneumonia
show
crp
level
declin
significantli
within
hour
initi
adequ
antibiot
therapi
patient
receiv
inadequ
antibiot
therapi
declin
least
crp
hour
sensit
specif
effect
antibiot
therapi
final
amongst
hospit
patient
sever
communityacquir
pneumonia
appropri
antibiot
therapi
associ
decreas
crp
day
antibiot
therapi
decreas
day
thu
adequ
antibiot
therapi
gener
associ
signific
decreas
crp
day
therapi
howev
effect
may
pronounc
nonicu
patient
icu
patient
pct
amino
acid
precursor
calciumregul
peptid
calcitonin
normal
condit
gene
transcrib
pct
thyroid
ccell
cleav
form
calcitonin
pct
virtual
undetect
serum
healthi
individu
ngl
context
infect
howev
express
upregul
variou
tissu
includ
neuroendocrin
cell
liver
lung
adipocyt
macrophag
tissu
lack
abil
cleav
pct
calcitonin
lead
rapid
rise
serum
pct
level
express
pct
nonthryoid
tissu
stimul
bacteri
lipopolysaccharid
endotoxin
well
inflammatori
cytokin
convers
viral
mediat
interferong
inhibitori
effect
pct
express
howev
pct
entir
specif
bacteri
infect
noninfecti
caus
pct
elev
includ
neuroendocrin
malign
small
cell
lung
cancer
ccell
carcinoma
thyroid
gland
neuroendocrin
tumor
gastrointestin
tract
addit
caus
includ
acut
ill
cardiac
arrest
pancreat
rhabdomyolysi
trauma
final
pct
level
increas
postop
particularli
patient
undergo
intestin
surgeri
pct
elev
patient
noninfecti
inflamm
howev
typic
lower
bacteri
infect
context
bacteri
infect
pct
rise
rapid
onset
hour
halflif
hour
peak
pct
level
occur
hour
onset
symptom
clearanc
pct
also
compar
rapid
pct
level
fall
day
icu
admiss
nearnorm
level
day
even
septic
patient
pct
clearanc
slightli
delay
context
signific
renal
failur
patient
without
renal
failur
delay
clearanc
pct
suggest
treatment
failur
numer
studi
examin
util
pct
marker
infect
icu
patient
recent
metaanalysi
data
studi
determin
pool
sensit
specif
distinguish
infect
noninfecti
system
inflamm
across
studi
preval
infect
averag
rang
pct
cutoff
averag
ngml
subanalysi
compar
surgic
trauma
patient
medic
patient
show
pct
slightli
accur
surgic
trauma
patient
medic
patient
separ
metaanalysi
examin
pct
marker
bacteremia
hospit
patient
amongst
icu
patient
n
sensit
specif
pct
bacteremia
vs
noninfecti
inflamm
respect
author
calcul
optim
pct
cutoff
ngml
note
lowest
sensit
among
immunocompromis
patient
specif
pct
also
show
good
diagnost
accuraci
distinguish
bacteri
viral
infect
metaanalysi
two
pediatr
studi
adult
mening
studi
indic
pct
sensit
specif
diagnos
bacteri
vs
viral
infect
cutoff
rang
ngml
studi
patient
lifethreaten
viral
ill
includ
sar
influenza
also
confirm
low
level
pct
popul
cohort
studi
patient
n
document
pct
level
ngml
patient
compar
ngml
compar
group
sever
communityacquir
bacteri
pneumonia
n
pct
also
effect
distinguish
bacteri
infect
invas
fungal
infect
retrospect
studi
pct
level
patient
bacteremia
fungemia
show
pct
ngml
sensit
specif
distinguish
patient
gramneg
bacteremia
fungemia
separ
studi
immunocompromis
patient
show
significantli
higher
pct
level
patient
bacteremia
quartil
rang
ngml
patient
fungemia
quartil
rang
ngml
author
note
low
pct
ngml
combin
moder
elev
crp
mgl
specif
sensit
fungemia
popul
thu
elev
crp
level
context
low
pct
level
prompt
consider
nonbacteri
infect
pct
use
identifi
patient
postop
infect
prospect
studi
patient
undergo
elect
colorect
surgeri
report
pct
level
ngml
sensit
specif
major
anastomot
leak
requir
reoper
confirm
multicent
observ
trial
predic
procalcitonin
reveal
earli
dehisc
colorect
surgeri
includ
patient
undergo
elect
surgeri
malign
studi
pct
ngml
sensit
specif
anastomot
leak
patient
complic
eg
bleed
local
wound
infect
cardiac
problem
show
modest
elev
pct
median
ngml
cardiac
surgeri
patient
elev
pct
level
also
indic
postop
infect
cohort
cardiac
surgeri
patient
pct
ngml
pod
show
sensit
specif
diagnos
infecti
complic
includ
postop
pneumonia
mediastin
bacteremia
neurosurg
patient
pct
level
increas
routin
postop
wherea
crp
white
blood
cell
count
serum
pct
level
proven
use
diagnos
postop
infect
neurosurg
patient
howev
cerebrospin
fluid
csf
pct
level
may
help
case
seri
patient
bacteri
viral
postneurosurg
mening
show
pct
ngml
csf
sensit
specif
mening
although
postneurosurg
mening
group
small
patient
csf
pct
level
ngml
unfortun
studi
includ
neurosurg
patient
without
mening
recent
studi
china
examin
neurosurg
patient
suspect
postsurg
infect
csf
pct
averag
ngml
rang
ngml
noninfect
patient
wherea
csf
pct
averag
ngml
rang
ngml
infect
patient
author
calcul
sensit
specif
area
receiv
oper
curv
csf
pct
confid
interv
author
recommend
cutoff
ngml
pct
wide
studi
context
icuacquir
infect
one
studi
trauma
patient
admit
icu
averag
pct
level
day
prior
infect
diagnosi
ngml
rise
ngml
day
diagnosi
cohort
crp
show
almost
correl
infect
diagnosi
averag
mgl
day
prior
diagnosi
rise
mgl
day
diagnosi
prorata
trial
use
pct
reduc
patient
exposur
antibiot
icu
multicent
prospect
parallelgroup
openlabel
trial
studi
benefit
pctguid
antibiot
treatment
patient
pct
group
subject
two
intervent
pctguid
threshold
initi
antibiot
pctguid
threshold
discontinu
antibiot
onset
infecti
symptom
antibiot
initi
encourag
patient
pct
level
ngml
threshold
antibiot
initi
daili
pct
level
measur
discontinu
antibiot
encourag
pct
level
drop
ngml
ngml
least
decreas
peak
two
intervent
result
signific
decreas
antibiot
usag
vs
day
antibiot
exposur
per
inpati
day
without
correspond
increas
mortal
icu
length
stay
followup
studi
icu
netherland
follow
similar
format
show
reduct
antibiot
use
increas
mortal
length
icu
stay
also
demonstr
cost
save
associ
fewer
day
antibiot
howev
counterbalanc
cost
daili
pct
measur
author
calcul
pct
assay
cost
per
sampl
would
achiev
overal
cost
save
studi
center
third
multicent
trial
germani
show
modest
reduct
antibiot
usag
vs
day
antibiot
exposur
per
icu
day
howev
pct
test
perform
day
antibiot
therapi
treat
physician
overrul
algorithm
case
cast
doubt
practic
protocol
signific
differ
group
term
mortal
icu
length
stay
thu
pctguid
antibiot
prescrib
show
promis
reduct
unnecessari
antibiot
use
may
requir
daili
pct
test
efficaci
crp
pct
help
biomark
distinguish
infect
noninfecti
system
inflamm
icu
patient
metaanalys
suggest
similar
sensit
marker
diagnosi
infect
crp
vs
pct
pct
slightli
higher
specif
crp
vs
pct
cutoff
rang
mgl
crp
ngml
pct
extrem
elev
crp
mgl
pct
level
ngml
alway
prompt
suspicion
bacteri
etiolog
pct
may
also
help
distinguish
bacteri
infect
invas
viral
fungal
infect
patient
sever
viral
ill
sar
show
low
pct
level
patient
invas
fungemia
studi
requir
determin
appropri
cutoff
hospit
patient
crp
pct
use
help
diagnos
postop
nosocomi
infect
pct
show
greater
util
due
greater
specif
faster
clearanc
elev
pct
level
suggest
postop
infect
particularli
anastomot
leak
neurosurg
popul
csf
pct
level
may
also
help
marker
postop
mening
final
crp
pct
use
monitor
efficaci
antibiot
therapi
icu
patient
context
appropri
antibiot
therapi
crp
level
declin
start
day
treatment
failur
show
declin
crp
level
suggest
treatment
failur
pctguid
antibiot
treatment
protocol
effect
reduc
unnecessari
antibiot
use
reduc
antibiot
initi
encourag
earli
discontinu
daili
pct
level
may
requir
protocol
significantli
affect
physician
behavior
distinguish
infecti
noninfecti
inflamm
critic
ill
patient
challeng
crp
pct
help
adjunct
clinic
paramet
rel
inexpens
wide
avail
thu
ensur
use
forese
futur
understand
interpret
marker
correctli
import
clinician
crp
pct
help
distinguish
infecti
noninfecti
caus
system
inflamm
icu
patient
crp
sensit
specif
infect
use
cutoff
mgl
pct
sensit
specif
infect
use
cutoff
ngml
pct
also
use
distinguish
bacteri
infect
system
viral
fungal
infect
although
ideal
cutoff
remain
determin
crp
pct
level
decreas
within
day
initi
appropri
antibiot
therapi
failur
show
decreas
crp
pct
level
timefram
suggest
treatment
failur
pctguid
antibiot
treatment
protocol
use
guid
antibiot
initi
discontinu
therebi
reduc
unnecessari
use
antibiot
icu
sepsi
diagnosi
found
vari
success
clinic
context
center
reli
heavili
marker
other
eschew
use
almost
entir
chapter
present
evid
use
diagnosi
sepsi
manag
antibiot
therapi
intens
care
unit
context
keyword
biomark
creactiv
protein
procalcitonin
sepsi
system
inflammatori
respons
syndrom
abstract
diagnosi
sepsi
base
recognit
system
inflamm
organ
failur
context
incit
infect
sinc
none
diagnost
criteria
specif
sepsi
easi
confound
sepsi
noninfecti
caus
system
inflamm
includ
pancreat
cardiac
ischemia
bowel
perfor
vascul
pulmonari
embol
amongst
other
two
wide
use
biomark
creactiv
protein
procalcitonin
proven
promis
